Ieq Capital LLC Has $1.09 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Ieq Capital LLC lifted its position in shares of Royalty Pharma plc (NASDAQ:RPRX) by 20.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 42,815 shares of the biopharmaceutical company’s stock after purchasing an additional 7,184 shares during the period. Ieq Capital LLC’s holdings in Royalty Pharma were worth $1,092,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Swedbank AB increased its stake in Royalty Pharma by 10.3% during the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company’s stock valued at $310,308,000 after purchasing an additional 1,136,800 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Royalty Pharma by 58.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after buying an additional 1,103,341 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Royalty Pharma by 44.7% during the third quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock valued at $85,809,000 after buying an additional 936,900 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Royalty Pharma during the third quarter worth about $14,898,000. Finally, Geode Capital Management LLC raised its holdings in shares of Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock worth $205,562,000 after acquiring an additional 417,490 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 1.1 %

Shares of RPRX stock opened at $33.80 on Tuesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The company has a market capitalization of $19.48 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.31 and a beta of 0.49. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20. The company has a 50-day simple moving average of $29.36 and a two-hundred day simple moving average of $28.00.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Research analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 21st will be issued a $0.22 dividend. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.60%. The ex-dividend date of this dividend is Friday, February 21st. Royalty Pharma’s payout ratio is 60.69%.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of analyst reports. TD Cowen upgraded Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. StockNews.com upgraded Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Royalty Pharma has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.